VANCOUVER, BC / ACCESS Newswire / November 25, 2025 /Variational AI, a leading innovator in generative artificial ...
Smart multi-target drugs are redefining how we treat complex diseases by combining AI-driven discovery with mechanistic ...
Artificial intelligence (AI) is revolutionising how scientists study cancer and Type 1 diabetes and discover ways to fight them.
In today’s ACT Brief, we look at how artificial intelligence is reshaping drug development decisions across pharma, discuss ...
At the 2025 World Internet Conference in Wuzhen, the global spotlight once again turned to this picturesque water town in southern China, as leaders from the internet and technology innovation sectors ...
From target identification and molecular design to patient stratification and clinical trial optimization, artificial intelligence (AI) is showing remarkable promise in accelerating drug discovery and ...
For rare diseases, AI-driven repurposing fills a critical gap. With more than 7000 rare diseases and only a small percentage ...
Explore the role of AI in drug discovery and how it revolutionises research through machine learning insights and strategies.
Artificial intelligence (AI) for science has rapidly gained momentum at an extreme pace. Models trained on the scientific record are generating hypotheses and even running experiments in automated ...
Nil Adell-Mill is pioneering a new era of chemistry by teaching machines to innovate through biology-inspired models, ...
A Western-led interdisciplinary research team is using artificial intelligence (AI) to target a potentially harmful enzyme found in the human body ...
Eli Lilly expanded its artificial intelligence drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune candidates. China will lift its import ban on Illumina's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback